Skip to main content
Fig. 1 | Trials

Fig. 1

From: The effect of luseogliflozin on bone microarchitecture in older patients with type 2 diabetes: study protocol for a randomized controlled pilot trial using second-generation, high-resolution, peripheral quantitative computed tomography (HR-pQCT)

Fig. 1

The study design. The eligibility check is conducted and the patient’s informed consent is obtained at visit 1. Only the patients who satisfy the run-in criteria at visit 2 are enrolled in the study; they are randomized at a 1:1 ratio to the luseogliflozin group (administered luseogliflozin 2.5 mg) and the control group (administered metformin 500 mg). The bone microarchitecture of the patients is analyzed before (visit 2) and 48 weeks after the administration of each medication (visit 6). BMD bone mineral density, SD standard deviation, T2DM type 2 diabetes mellitus

Back to article page

Trials

ISSN: 1745-6215